Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Essential Healthcare News.
Press releases published on April 29, 2025
Ovation Marks 10 Years as America’s Leading IVF Laboratory Services Company
EIN Presswire
·
April 29, 2025
Ovation® Fertility is celebrating a decade serving patients and fertility specialists as America’s leading provider of IVF laboratory management services. BRENTWOOD, TN, UNITED STATES, April 29, 2025 /EINPresswire.com/ -- Brentwood, TN (April 29, 2025) …
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025
GlobeNewswire
·
April 29, 2025
FREMONT, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Continuing its commitment to advancing cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) is showcasing its patented Full Spectrum Profiling™ (FSP®) technology at CYTO 2025 and American Association of …
Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew
GlobeNewswire
·
April 29, 2025
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, …
Knight to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
·
April 29, 2025
MONTREAL, April 29, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a …
Knight présentera à la conférence des investisseurs en santé Bloom Burton & Co. 2025
GlobeNewswire
·
April 29, 2025
MONTRÉAL, 29 avr. 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD), société pharmaceutique spécialisée panaméricaine (ex-ÉU), a annoncé aujourd'hui que Samira Sakhia, présidente et chef de la direction, présentera une mise à jour corporative …
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
GlobeNewswire
·
April 29, 2025
Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not …
CooperCompanies Announces Release Date for Second Quarter 2025
GlobeNewswire
·
April 29, 2025
SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, …
Certara to Participate in Upcoming Investor Conferences
GlobeNewswire
·
April 29, 2025
RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: BofA Securities 2025 …
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire
·
April 29, 2025
-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company’s Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc ( …
The Ensign Group Reports First Quarter 2025 Results; Raises Annual Earnings and Revenue Guidance
GlobeNewswire
·
April 29, 2025
SAN JUAN CAPISTRANO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign(TM) group of companies, which provide post-acute healthcare services and invest in the long-term healthcare industry, …
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
GlobeNewswire
·
April 29, 2025
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active …
Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern Time
GlobeNewswire
·
April 29, 2025
GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people …
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting
GlobeNewswire
·
April 29, 2025
ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling …
PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June
GlobeNewswire
·
April 29, 2025
SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of …
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
GlobeNewswire
·
April 29, 2025
- $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study for hypochondroplasia Phase 2 trial fully enrolled …
BeautyHealth to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 29, 2025
LONG BEACH, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report first quarter 2025 financial results after market close on Thursday, May 8, 2025. The …
Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire
·
April 29, 2025
ART0380 in combination with low-dose irinotecan demonstrated a 50% confirmed overall response rate (cORR) in patients with Ataxia-Telangiectasia Mutated (ATM)-negative1 solid tumors at the recommended Phase 2 dose (RP2D) 37% cORR observed in patients with …
Nouscom Presents Positive Final Results from Completed Phase Ib/II Study of Neoantigen Immunotherapy NOUS-209 at AACR 2025, Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers
GlobeNewswire
·
April 29, 2025
Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of cancer, especially colorectal and endometrial, to as high as 80% NOUS-209 is an off-the-shelf immunotherapy designed to harness the power of the immune …
Intrinseque Health Announces Plans to Establish State-of-the-Art GMP-Certified Warehouse in Melaka, Malaysia.
EIN Presswire
·
April 29, 2025
Intrinseque Health announces plans to establish a GMP-certified warehouse in Melaka, Malaysia, reinforcing its global clinical supply chain expansion strategy. MELAKA, MALAYSIA, April 29, 2025 /EINPresswire.com/ -- As part of its continued commitment to …
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
GlobeNewswire
·
April 29, 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, …